Stifel analyst Paul Matteis lowered his price target for Alkermes to $23 from $25 and reiterates a Hold rating on the shares. The Q3 results were a "mixed bag," as the misses for Aristada and Vivitrol were balanced by the restructuring announcement, Matteis tells investors in a post-earnings research note. Investors will be happy to see some cost discipline from Alkermes, as the company's margin expansion story "hasn't played out as well as some investors had hoped," adds the analyst. Matteis reduced some of his long-term Vivitrol and Aristada projections.